1.050USD+0.01%Mkt Cap: 5.37M USDP/E: —Last update: 2026-05-26
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline in…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap5.37M USD
Enterprise Value2.45M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-18.65M USD
Revenue/Share—
Last Price1.050 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees15
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.23
PEG—
EV/EBITDA-0.15
EV/Revenue—
P/S—
P/B0.57
EPS (TTM)-7.02
EPS (Forward)-4.49
52W Range
0.95201% of range19.80
52W High19.80 USD
52W Low0.9520 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-302.89%
ROA-193.85%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-16.39M USD
CapEx (TTM)262.00K USD
FCF Margin—
FCF Yield-185.79%
Net Debt-2.48M USD
Net Debt/EBITDA0.15
Balance Sheet
Debt/Equity0.39
Current Ratio3.61
Quick Ratio2.78
Book Value/Sh1.851 USD
Cash/Share1.448 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateMar 30, 2026
Analyst Consensus
Rating—
Target (Mean)13.50 USD
Target Range8.000 USD – 19.00 USD
# Analysts2
Ownership
Shares Out.5.21M
Float2.99M
Insiders12.62%
Institutions7.18%
Short Interest
Short Ratio0.1d
Short % Float2.37%
Short % Out.2.20%
Shares Short99.97K
Short (prev mo.)43.68K
Technical
SMA 502.288 (-54.1%)
SMA 2006.531 (-83.9%)
Beta1.10
S&P 52W Chg28.31%
Avg Vol (30d)316.13K
Avg Vol (10d)442.66K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—